Patent Application
20080096979
The present invention relates to novel stable aqueous coating dispersions of wax or combination of waxes.
The present invention also relates to pharmaceutical, food and cosmetic applications of the novel aqueous coating dispersions of wax or combination of waxes.
In particular the pharmaceutical applications include taste masking, stabilization and release retardation of drugs.
Pharmaceutical dosage forms are coated for various reasons including (1) protecting the drug from its surrounding environment (particularly air, moisture, and light) with a view to improving stability, (2) masking of unpleasant taste and odour, (3) increasing the ease by which the product can be ingested by the patient, (4) improving the product identity, (5) facilitating handling, particularly high speed packaging/filling lines, and automated counters in pharmacies, where the coating minimizes cross-contamination due to dust elimination, (6) improving product appearance, particularly where there are noticeable visible differences in the tablet core ingredients from batch to batch, (7) reducing the risk of interaction between incompatible components, (8) improving product mechanical integrity, since coated products generally are more resistant to mishandling (abrasion, attrition, etc), (9) modifying drug release, as in enteric-coated, repeat-action and sustained-release products.
Pharmaceutical dosage forms are coated using various polymeric or non-polymeric materials dissolved or dispersed in an aqueous or non-aqueous solvent. Use of organic solvents has faced a lot of regulatory restrictions over time due to its inherent cumbersome procedures leading to undesirable effects. These include explosion, fire hazard, toxic release, all of which lead to environmental pollution. Due to the regulatory and manufacturing issues, pharmaceutical companies are rapidly replacing the organic solvents based coating procedures with aqueous film coating processes.
In the past, waxes have been employed for coating, which give better retardation of drug release due to their hydrophobic nature compared to hydrophilic polymers. However their use has been restricted to non-aqueous methods or hot melt techniques. Use of wax in the hot melt technique involves melting of the wax which is then employed in various processes such as granulation, spray coating and extrusion-spheronisation. These methods involve cumbersome procedures and require special equipments. In addition, in case of hot melt—technique, during coating stage, the drug is exposed to high temperature, which is not preferred as it may alter or degrade the drug substance.
In prior art are described applications of coating of pharmaceutical products to achieve taste masking, stabilization and release retardation of drugs. These are described below:
U.S. Pat. No. 5,151,433 discloses coating of drug with a protective polymeric coat. The object of the invention is to protect the labile drug from mechanical stress encountered during compression by using a polymer. The patent describes only polymers as protective agent and waxes as protective agent is not anticipated by this invention.
A multiparticulate controlled release selective serotonin reuptake inhibitor (SSRI) formulation for oral administration is claimed in WO 00/71099A1. The formulation comprises particles of drug coated with rate-controlling polymer, which allows controlled release over a period of not less than about 12 hours. The instant invention makes use of wax for rate controlling instead of polymer claimed in the WO 00/71099A1. The polymeric plasticizer employed in the present invention only helps to produce the uniform film and does not retard the release of the active ingredient.
U.S. Pat. No. 6,448,323 describes a dry film coating composition for use in coating pharmaceutical tablets, nutritional supplements, food, confectionery forms, agricultural seeds, and the like, comprises polyvinyl alcohol, a plasticizer such as polyethylene glycol or glycerin, talc, and preferably a pigment/opacifier and lecithin. This patent also describes a film coating composition, however no wax is employed in the coating composition.
None of the above mentioned prior art applications describe use of waxes as a coating agent more particularly from an aqueous base. Thus there is a long felt need in the pharmaceutical industry to have coating dispersions that are not only aqueous based but also have the advantages provided by using wax as a coating agent.
US2001019725 relates generally to a method of manufacture of controlled release particles containing drug, carrier wax and an excipient by hot melt and mechanical processes. U.S. Pat. No. 6,238,704 relates to a process for preparing a sustained-release formulation by: 1) coating drug containing granules successively with layers of wax, ethyl cellulose containing a plasticizer and a water soluble polymer followed by 2) heating at 50-90° C.
The above two prior art examples utilize heat to melt the waxy components unlike the present invention which utilizes coating with an aqueous wax emulsion.
U.S. Pat. No. 5,023,108 relates to a process for coating of pharmaceutical solids using an aqueous wax emulsion (prepared from a spray dried mixture) containing waxes or lipids alone or in combination in the range of 10 to 30%. PCT application WO04083310 describes the preparation and use of a water-wax emulsion, comprising: about 10% to about 50% of a hydrogenated vegetable wax; about 50% to about 90% by weight water; about 1% to about 25% by weight of a surface-active agent, and about 0.02% to about 2.5% of an acid or base, based on the total weight of the emulsion. Applications described include coating of fibrous cellulosic products to improve moisture resistance.
The above two patents describe use of aqueous emulsions containing wax or waxes for coating: However these emulsions contain 10-30% and 10-50% of waxes in comparison with the present invention, which employs wax contents of up to about 10%.
The inventors have found that aqueous wax coating dispersion with upto about 10% of wax and the use of a plasticizer in the emulsified wax results in a continuous, uniform film formation of the wax, demonstrating excellent coating properties and exhibiting all the desirable qualities of an aqueous base coating medium. The coating dispersion described herein has the advantage of aqueous base as against organic solvents that are commonly employed for coating application involving waxes.
It is thus an object of the invention to provide aqueous-based wax coating dispersions that overcome problems associated with prior art.
It is another object of the present invention to provide a stable aqueous coating dispersion of waxes for coating solid dosage forms.
It is yet another object of the invention to provide wax coating dispersions that combine the advantages of having an aqueous coating base and wax as coating agent.
Another object of the present invention is to provide wax coating dispersions having emulsified wax in combination with a plasticizer rendering stable and uniform film formation.
Another object of the present invention is to provide aqueous wax coating dispersions that retard the release of the drug from the dosage form.
Yet another object of the present invention is to provide aqueous wax coating dispersions that improve the stability of the active compounds.
Yet another object of the present invention is to provide aqueous wax coating dispersions for masking the bitter taste of active ingredients.
Thus according to an aspect of the present invention, there is provided a novel aqueous wax coating dispersion for coating of pharmaceutical dosage forms comprising
According to second aspect of the present invention, there is provided a process of making the novel aqueous wax coating dispersions having water soluble plasticizer comprising steps of:
According to yet another aspect of the present invention, there is provided a process of coating solid pharmaceutical formulations with the novel aqueous wax coating dispersions for water insoluble plasticizer comprising steps of
The active composition of the novel aqueous wax coating dispersions described herein is preferably used in coating solid pharmaceutical formulations including but not limited to powders, tablets, granules, pellets, capsules or other suitable solid dosage form.
The present invention addresses the need for an aqueous wax coating dispersion which can be used for various purposes like retardation of and pulsatile and extended release, taste masking and stabilization of drug substances. According to the invention, the composition of an aqueous wax coating dispersion typically contains in an aqueous medium;
The compositions of the present invention are discussed in greater detail with respect to the individual ingredients as hereunder:
Wax Component:
Waxes can be individual or mixtures of esters of monohydroxy alcohols, besides other esters and free fatty acids, free alcohols, higher hydrocarbons and natural or hydrogenated oils. Among the waxes derived from plants are carnauba wax and candelilla wax. The waxy substance secreted by glands on the abdomen of the bee is known commonly as beeswax. Waxes of animal origin include wool wax, or lanolin; spermaceti, and Chinese wax. Mineral waxes include ozocerite and paraffin, both composed of hydrocarbons. Japan wax and bayberry (or myrtle) wax are composed chiefly of fats.
Waxes form excellent barrier coatings for moisture sensitive drugs. The system protects the drug molecules from atmospheric moisture without affecting the active ingredient thus providing good stability and protection for hygroscopic drugs. Waxes are also used as retarding agents for drug release.
The preferred wax according to the present invention is selected from carnauba wax, candelilla wax, spermaceti, bees wax, montan wax, microcrystalline wax, lecithin, hydrogenated tallow, paraffin wax, cetyl alcohol, cetostearyl alcohol, stearic acid hydrogenated vegetable oil such as hydrogenated cottonseed oil (Lubritab™), hydrogenated soyabean oil (sterotex HMNF™), compritol, precirol, shellac wax, petrolatum, and the like as well as synthetic waxes, e.g., polyethylene, and the like. These waxes can be used alone or in combinations.
Wax may be used at a concentration of up to about 10% by weight.
The preferred percentage wax according to present invention is 0.5%-9% by weight
The most preferred percentage wax according to present invention is about 2.5-7.5% by weight.
Emulsifying Agent:
Emulsifying agent or Emulsifiers generally classified as surfactants and have hydrophilic and lipophilic structural portions within their molecular structures. Pharmaceutically acceptable emulsifiers should also be stable, compatible with other ingredients and non-toxic. It should possess little odor, taste or color and should not interfere with the stability of efficacy of the active agent. The emulsifier may be selected from hydrophilic surfactants or lipophilic surfactants or mixtures thereof. The surfactants may be anionic, nonionic, cationic, and zwitterionic surfactants.
The preferred emulsifying agents according to the present invention are selected from non-ionic emulsifiers like mono- and diglycerides, medium chain glyceride (Capmul) glyceryl monooleate (Peceol), glyceryl ricinoleate, glyceryl laurate and glyceryl caprylate (Capmul MCM), PEG sorbitan fatty acid esters like PEG ˜20 sorbitan monolaurate (Tween 20), PEG 20 sorbitan monostearate (Tween 60) and PEG sorbitan monooleate (Tween 80), Sorbitan fatty acid esters like sorbitan monolaurate (span 20), sugar ester surfactants like sucrose distearate (sucro ester 7), ionic emulsifiers like sodium caprylate sodium lauryl sulphate, phospholipids, alginate salts. These emulsifiers can be used alone or in combinations.
The emulsifying agent is employed at a percentage of about 0.1-10% by weight.
The preferred percentage of emulsifying agent according to present invention is about 0.5-7.5% by weight
The most preferred percentage of emulsifying agent according to present invention is 0.75-5.0%, by weight of the total composition.
Plasticizer:
Plasticizers are used to improve the processibility, flexibility, and elasticity of coating agents. These plasticizing compounds also reduce the brittleness, and improve the toughness and tensile strength of the coating agents. They play an important role in the film formation process. The quality of the resulting film is dependent on the type and amount of plasticizer added to the coating medium. According to the present invention, plasticizers may be polymeric or non-polymeric and soluble or insoluble in water.
The preferred plasticizer according to the present invention is selected from polymers like ammonio methacrylate co-polymer, Eudragit RL, Eudragit RS, polyvinyl alcohol, polyvinylpyrrolidone, polyvinyl acetate, mixture of polyvinyl acetate with povidone (Kollidone SR™) methylcellulose, ethyl cellulose, sodium carboxy methylcellulose, hydroxypropylcellulose, hydroxypropylmethyl cellulose or polyethylene glycol, cellulose acetate cellulose propionate (lower, medium or higher molecular weight), cellulose acetate propionate, cellulose acetate butyrate, cellulose acetate phthalate, cellulose triacetate, poly (methyl methacrylate), poly (ethyl methacrylate), poly (butyl methacrylate), poly (isobutyl methacrylate), and poly (hexyl methacrylate), poly (isodecyl methacrylate), poly (lauryl methacrylate), poly (phenyl methacrylate), poly (methyl acrylate), poly (isopropyl acrylate), poly (isobutyl acrylate), poly (octadecyl acrylate), poly (ethylene), poly (ethylene) low density, poly (ethylene) high density, poly (ethylene oxide), poly (ethylene terphthalate) poly (vinyl isobutyl ether), poly (vinyl acetate), poly (vinyl chloride) or polyurethane, polymers based on acrylate and/or methacrylates) or any of the polymers with similar plasticizing function.
The preferred plasticizer according to the present invention may also be selected from nonpolymeric plasticizers like propylene glycol, glycerine, triethyl citrate, dibutyl sebacate, gelucire 39/01, gelucire 43/01 or any of the nonpolymeric plasticizer with similar plasticizing function.
The chosen plasticizer can be used individually or in combinations.
The plasticizer is employed at a concentration of 5 to 40% by weight of the wax, preferably 7.5% to 35% by weight of the wax, and more preferably 10%-30% by weight of the wax.
Process
The procedures for preparation of aqueous wax coating dispersion containing wither a water soluble or water insoluble plasticizer are described below:
The process for a water soluble plasticizer comprises steps of:
The dispersion obtained from any of the above process can be screened through a 150 micron (100#) sieve in order to confirm the absence of any insoluble material and an uniformity of the dispersion.
Applications
According to the present invention the aqueous wax coating emulsion can be employed to apply a wax coat to any suitable solid pharmaceutical form, e.g. drug particles, granules, pellets, tablets, capsules, patches, films. The wax-coated particulates may be compressed or suitably processed into a dosage form.
Wax coating, according to the current invention, is aimed at achieving stabilization, taste masking and modification of release of a drug substance. One skilled in the art will also appreciate that the coating dispersion described herein can replace any polymer coating known thus far in the field of pharmaceutical coating. Stabilization of drug substance can be in respect of hydrolytic, oxidative or any other form of degradation. Modified drug release can be in the form of sustained, pulsatile, delayed, or targeted release.
The details of the invention, its objects and advantages are explained hereunder in relation to non-limiting exemplary illustrations.
Lubritab and Capmul MCM were heated in a water bath at 80° C.-85° C. A part of the water was heated to 90° C. and added to the molten waxy mass with constant stirring using a suitable laboratory stirrer to obtain a smooth emulsion. The emulsion was cooled to room temperature. The plasticizer was dissolved in the remaining water, and added to the above emulsion under stirring. A stable and uniform dispersion was obtained.
Sterotex and Capmul MCM were heated in a water bath at 70° C.-80° C. A part of the water was heated to 90° C. and added to the molten waxy mass with constant stirring using a suitable laboratory stirrer to obtain a smooth emulsion. The emulsion was cooled to room temperature. The plasticizer was dissolved in the remaining quantity of water and added to the above emulsion under stirring. A stable and uniform dispersion was obtained.
The aqueous wax coating dispersion prepared in Example 1 and Example 2 were observed visually for physical stability such as cracking (separation of phases) or creaming of oil droplets at the surface after 1, 7, 15 and 30 days storage at the ambient.
It was observed that both the compositions were stable at the end of 30 days as shown by absence of creaming and cracking.
Lubritab, Gelucire 39/01 and Capmul MCM were heated in a water bath at 80° C.-85° C. A part of the water was heated to 90° C. and added to the molten waxy mass with constant stirring using a suitable laboratory stirrer to obtain a smooth emulsion. The emulsion was cooled to room temperature. The remaining quantity of water was added to the above emulsion under stirring.
A uniform dispersion was obtained which was observed to be stable on storage.
Hydrogenated cottonseed oil was heated in a water bath at 80° C.-85° C. A 10% solution of Polyoxyethylene 20 sorbitan monooleate heated to 90° C., was then added to the molten lipid mass with constant stirring using a suitable laboratory mixer. A 4% dispersion of Veegum in water was heated to 90° C. and added with stirring to above dispersion. The crude emulsion thus formed was then homogenized and shock-cooled in an ice-bath with constant stirring, a solid, mass (gritty particles) was formed.
This observation demonstrates the inadequacy of this prior art system and the superiority of the compositions of the present invention through the use of a plasticizer and lower levels of wax content.
Hydrogenated vegetable oil and Capmul MCM were heated in a water bath at 80° C.-85° C. A part of the water was heated to 90° C. and added to the molten waxy mass with constant stirring using a suitable laboratory stirrer to obtain a smooth emulsion. The emulsion diluted with remaining quantity of water and cooled to room temperature.
Films were cast using above emulsion and dispersion of Example 1 and dried at 40° C. for 6-8 hours.
Films obtained with dispersion of Example I were smooth and had minimum cracks whereas films of above dispersion gave discontinuous, cracked appearance. This data indicates the need of using a plasticizer in the aqueous wax coating dispersion. Plasticizer helps to reduce the brittleness of the film and improves the tensile strength of the film which is essential for a coating dispersion.
Hydrogenated vegetable oil and Capmul MCM were heated in a water bath at 80° C.-85° C. A part of the water was heated to 90° C. and added to the molten waxy mass with constant stirring using a suitable laboratory stirrer to obtain a smooth emulsion. The emulsion was cooled to room temperature. In the remaining quantity of water, the plasticizer was dissolved and added to the above emulsion under stirring.
A uniform dispersion was obtained, which showed desirable stability on storage.
Hydrogenated vegetable oil and Capmul MCM were heated in a water bath at 80° C.-85° C. A part of the water was heated to 90° C. and added to the molten waxy mass with constant stirring using a suitable laboratory stirrer to obtain a smooth emulsion. The emulsion was cooled to room temperature. In the remaining quantity of water, the plasticizers were dissolved and added to the above emulsion under stirring.
A uniform dispersion was obtained which was stable on storage.
Hydrogenated vegetable oil and Capmul MCM were heated in a water bath at 80° C.-85° C. A part of the water was heated to 90° C. and added to the molten waxy mass with constant stirring using a suitable lab stirrer to obtain a smooth emulsion. The emulsion was cooled to room temperature. In the remaining quantity of water, plasticizers in the form of aqueous dispersions were mixed and added to the above emulsion under stirring.
Uniform dispersions were obtained which showed good stability on storage.
Cetostearyl alcohol and Capmul MCM were heated in a water bath at 80° C.-85° C. A part of the water was heated to 90° C. and added to the molten waxy mass with constant stirring using a suitable lab stirrer to obtain a smooth emulsion. The emulsion was cooled to room temperature. In the remaining quantity of water, plasticizer was dissolved and added to the above emulsion under stirring.
A uniform stable dispersion was obtained.
Compritol and Capmul MCM were heated in a water bath at 80° C.-85° C. A part of the water was heated to 90° C. and added to the molten waxy mass with constant stirring using a suitable lab stirrer to obtain a smooth emulsion. The emulsion was cooled to room temperature. In the remaining quantity of water, plasticizer was dissolved and added to the above emulsion under stirring.
A uniform stable dispersion was obtained.
Hydrogenated Vegetable oil and Tween 80 were heated in a water bath at 80° C.-85° C. A part of the water was heated to 90° C. and added to the molten waxy mass with constant stirring using a suitable lab stirrer to obtain a smooth emulsion. The emulsion was cooled to room temperature. In the remaining quantity of water, plasticizer was dissolved and added to the above emulsion under stirring.
A uniform stable dispersion was obtained.
Sterotex and Capmul MCM were heated in a water bath at 70° C.-80° C. A part of the water was heated to 90° C. and added to the molten waxy mass with constant stirring using a suitable laboratory stirrer to obtain a smooth emulsion. The emulsion was cooled to room temperature. In the remaining quantity of water, the plasticizer was dissolved and added to the above emulsion under stirring. In this example following variables were attempted:
Composition A: Wax 9.5% w/w and plasticizer—40% by weight of wax, which is as per the present invention
Composition B: Wax 12% w/w and plasticizer—40% by weight of wax
Composition C: Wax 12% w/w and plasticizer—30% by weight of wax
Composition D: Wax 12% w/w and plasticizer—15% by weight of wax
It was observed that at 9.5% w/w of wax a smooth and uniform, sprayable dispersion was obtained, however at 12% w/w of wax, the emulsion was very thick, had gritty appearance which can not be sprayed for coating purposes. Even with plasticizer concentration of 15% by weight of wax (Example D), the dispersion was not sprayable.
This clearly demonstrates that above 10% w/w concentration of wax, the dispersion loses its liquid consistency and cannot be used as a coating agent.
Drug used: Metformin Hydrochloride
Dosage form: Tablets
(a) Preparation of Tablets for Coating:
Metformin hydrochloride and PVP K-30 weighed and sifted through mesh 40 and loaded in a Planetary Mixer and mixed for 10 minutes and then granulated using demineralized water. The wet mass was then dried in fluidized bed dryer at inlet air temperature of 60° C. and bed temperature at 45° C. The dried granules were then passed through mesh 16 and lubricated with magnesium stearate and compressed using capsule shaped punches.
(b) Coating of Tablets Using Aqueous Wax Coating Dispersion of Example 1:
800 g of Metformin tablets were placed in the coating equipment. The tablets were sprayed with the coating dispersion of Example 1 employing methods known in the art. The inlet temperature was kept at 60° C. The spraying was carried out continuously until the desired increase in mean weight of tablets was achieved. Tablets thus obtained had a smooth and lustrous surface.
Dissolution profiles indicate that at a coating of 18%, a lagtime of about one hour in the release of metformin was observed and in the next 1 hour about 80% of the drug was released. This suggests that aqueous wax coating can be employed to develop pulsed delivery systems with a defined lag period.
(c) Coating of Tablets Using Aqueous Wax Coating Dispersion of Example 2:
200 g of Metformin tablets were placed in the coating vessel of fluidized bed processor. The tablets were sprayed with the coating emulsion of Example 2 according to the methods known in the art. The inlet temperature was kept at 60° C. The spraying was carried out continuously until the desired increase in mean weight of tablets was achieved. Tablets thus obtained had a smooth and lustrous surface.
At both the coating levels after a lag period of 2 hour a sustained release of drug was obtained over 8 hours.
These results indicate that pulsed or sustained release of a highly water soluble drug such as metformin can be achieved by selecting appropriate coating dispersion composition and coating level.
(a) Preparation of Metoprolol Succinate Pellets
Drug and Pharmacel 101 were sifted together through mesh 40 (425 micron) and mixed in low shear mixer. Povidone was dissolved in the required quantity of water. This solution was added to the above mixture under mixing till a wet mass of proper consistency was obtained. The wet mass was then extruded through an extrudor using a 0.5 mm size cone plate attachment and spheronised. The pellets were dried at 50° C. for 10 min
(b) Preparation of Aqueous Wax Coating Dispersion
Hydrogenated vegetable oil and Capmul MCM were heated in a water bath at 80° C.-85° C. A part of the water was heated to 90° C. and added to the molten waxy mass with constant stirring using a suitable lab stirrer to obtain a smooth emulsion. The emulsion was cooled to room temperature. In the remaining quantity of water, plasticizer was dissolved and added to the above emulsion under stirring.
(c) Coating of Metoprolol Succinate Pellets:
80 g of pellets (#20 to #60) were placed in the coating vessel of fluidized bed processor. The pellets were sprayed with the above dispersion according to the method known in the art. The inlet temperature was kept at 50° C. The spraying was carried out continuously until the desired coating level was achieved. Pellets thus obtained had a smooth and lustrous surface. Coated beads were then filled into capsules and dissolution was carried out in pH 6.8 phosphate buffer.
These data suggest that using aqueous wax coating dispersion of present invention, it is possible to coat pellets and retard release of a highly water soluble drug such as metoprolol.
(a). Preparation of Diclofenac Tablets
Starch, Lactose and Diclofenac sodium were granulated using a solution of polyvinyl pyrrolidone in purified water and dried in fluidized bed dryer till desired moisture content is achieved. Granules were then blended with other excipients, lubricated and compressed into tablets using 7.0 mm standard concave punches.
(b) Coating of Tablets:
Tablets were coated in a conventional coating pan using aqueous wax coating dispersion containing Sterotex HMNF (Refer composition Example 2). Samples of coated tablets were collected at 5%, 10%, 15% and 20% weight gain levels and release of active agent was determined using pH 6.8 phosphate buffer as dissolution medium.
The results suggest that controlled release of a drug having intermediate solubility in water can be obtained using aqueous wax coating dispersions of present invention.
(a) Preparation of Tibolone Pellets:
Drug, Lactose and microcrystalline cellulose were sifted together through mesh 40 (425 micron) and mixed in low shear mixer. Povidone was dissolved in the required quantity of water and added to the above mixture under mixing till a wet mass of proper consistency obtained. The wet mass was then extruded through an extrudor using a 0.5 mm size cone plate attachment and spheronised. The pellets were dried at 40° C.
(b) Preparation of Coating Dispersions
(a) Process for preparing aqueous wax coating dispersion was same as given in example 2
(b) In the half of the amount of water, PEG 8000 was dissolved and talc was dispersed in it. HPMC was dissolved in the remaining amount of water and added to above dispersion. The suspension was filtered through #100 mesh (150 micron)screen
(c) Coating of Tibolon Pellets:
Pellets (#20 to #60) were placed in the coating vessel of fluidized bed processor. The pellets were sprayed with the above coating dispersion (either a or b) according to the method known in the art. The inlet temperature was kept at 45° C. The spraying was carried out continuously until the desired coating level was achieved. Pellets thus obtained had a smooth and lustrous surface. Coated beads were then exposed at accelerated conditions of 40° C./38% RH and 40° C./75% RH for 15 days. The levels of impurity C of tibolon were determined using HPLC for the uncoated, HPMC coated and aqueous wax dispersion coated beads.
Under both the accelerated conditions, it was found that the amount of impurity C was lowest for beads coated with the aqueous wax dispersion, suggesting that the aqueous wax coating dispersion can be employed to stabilize actives sensitive to temperature and/or moisture.
(a) Preparation of Ascorbic Acid Tablets
Vitamin C was granulated using molten Compritol. The mass was cooled to room temperature and further blended with Kollidone SR, Kollidone VA 64 and magnesium stearate. The blend was compressed using capsule shaped punches.
(b) Coating of Tablets:
The compressed tablets were coated in a conventional coating pan with wax coating dispersion of example 2 till a coating level of 5% was achieved.
Both coated and uncoated tablets were placed in an open petriplate at 40° C./75% RH. After a week it was observed that the color of the uncoated tablets had changed to dark yellow both on the surface as well as inside the tablet (observed by cutting tablets into two halves) indicating degradation of ascorbic acid. However, the coated tablets were only pale yellow in color when tablets were cut into two halves. This example also suggest that aqueous wax coating dispersion can be employed to stabilize actives which may be susceptible to degradation either by oxidation, heat or humidity or a combination of these.
Phenytoin sodium shows incompatibility and discoloration when physically mixed with lactose in pharmaceutical compositions. Wax coating approach was applied to stabilize the phenytoin in presence of lactose.
Plain phenytoin sodium was sifted through 40 # and mixed with MCC (Avicel PH 102) [1:1 ratio] and the mixture was loaded in fluidized bed processor. Coating of this mixture was carried out using wax coating dispersion of example 2.
The phenytoin sodium-MCC mixture with a wax coating level of 10%, was used for the physical incompatibility study by mixing with lactose (pharmatose 200 M) in a 1:2 ratio. The mixture was sifted through 40# and the samples were subjected to an accelerated stability study at room temperature and 40 degree/75% RH. A blend of uncoated phenytoin sodium-MCC mixture with Lactose (pharmatose 200) in the 1:2 was used as positive control. Samples were observed for physical changes in appearance and color.
After an exposure for 3 days the color of the uncoated phenytoin blend had changed to yellow-whereas coated phenytoin remained only slightly colored. Thus aqueous wax coating dispersion can be employed to prevent drug excipient interaction and thereby stabilize the drug.
Drug used: Ursodiol
Dosage form: Dispersible Tablets
(a) Preparation of Aqueous Wax Coating Dispersion
The coating dispersion was prepared as described in Example 1. This wax emulsion was used as a binder in the preparation of Ursodiol tablets.
(b) Preparation of Tablets
Ursodiol was granulated with the wax emulsion and the granules thus obtained were mixed with mannitol, passed through mesh 8 and then dried in the tray dryer at 45° C. The dried granules were then passed through mesh 20 and mixed with the remaining excipients and compressed into tablets.
(c) Evaluation of Tablets with Respect to Taste in Human Volunteers
A panel of 10 human volunteers was selected. These tablets were dispersed in 15 ml of water and this dispersion was given to all the volunteers. The bitter taste of ursodiol was masked and the tablets were acceptable with respect to overall mouthfeel, taste and palatability.
Thus, granulation with aqueous wax dispersion can be employed for masking the bitter taste of drug such as ursodiol and this drug subsequently incorporated into dispersible tablet formulations.
(a) Preparation of Powder Blend of Cetirizine Hydrochloride with F-Melt
Accurately weighed amounts of cetirizine hydrochloride and F-melt were passed through 40# and mixed to obtain uniform blend.
(b) Coating of Blend of Cetirizine Hydrochloride-F-Melt
The blend of Cetirizine hydrochloride-F-melt was placed in the coating vessel of fluidized bed processor. The blend was sprayed with the coating emulsion of example 16 employing methods known in the art. The inlet temperature was kept at 60° C. The spraying was carried out continuously until the desired coating level of 6% was achieved.
(c) Preparation of Mouth Dissolve Tablets
F-melt, xylisorb and polyplasdone were weighed, sifted through 40 # and mixed uniformly. The above blend was then mixed with wax coated drug for 10 mins. Weighed amounts of sweeteners and flavors were sifted through 60# and mixed with above blend to obtain uniform mixture. The entire blend was then passed through 40 # and remixed. The above blend was then lubricated with magnesium stearate and compressed to tablets using capsule shaped punches on a compression machine.
The above process was also followed for plain uncoated cetirizine hydrochloride as control samples.
(d) Evaluation of Tablets with Respect to Taste and Mouth Feel in Human Volunteers
A panel of 10 human volunteers was selected and all the volunteers were given one tablet each of both the samples i.e. wax coated cetirizine hydrochloride tablets and uncoated tablets. These tablets were kept on the tongue and ratings were given with respect to overall mouthfeel, taste and palatability.
It was observed that the wax coated formulations showed much greater acceptance from all volunteers with respect to all the parameters, namely taste, mouth feel and overall palatability compared to uncoated tablets. Thus, coating with aqueous wax dispersion can be employed for masking the bitter taste of drug such as cetirizine hydrochloride and the coated drugs subsequently incorporated into mouth dissolve tablet Formulations.
(a) Preparation of Tablets
Dicalcium Phosphate and povidone were dry mixed and granulated with water. The wet mass was dried at 40° C. for 30 min in tray drier and then mixed with Pseudoephedrine hydrochloride. The blend was lubricated and compressed into tablets.
(b) Coating of Tablets
The tablets were placed in the coating vessel of a fluidized bed processor. The tablets were sprayed with the coating emulsion of Example 2 employing methods known in the art. The inlet temperature was kept at 60° C. The spraying was carried out continuously until the desired coating level was achieved. The process was continued for coating levels of 3% and 5%.
(c) Evaluation of Tablets with Respect to Perception of Bitter Taste
A panel of 10 healthy human volunteers was selected and all the volunteers were given one tablet each of both the samples i.e. wax coated Pseudoephedrine tablets and uncoated Pseudoephedrine tablets as control. The time required for perception of bitter taste was recorded by volunteers. For uncoated tablets, the bitter taste of drug was perceived immediately (within one minute). However for wax coated tablets, the bitterness was not perceived even after 5 minutes. Thus, aqueous wax coating dispersion can be employed tor masking the bitter taste of drugs incorporated into a tablet.
| Number | Date | Country | Kind |
|---|---|---|---|
| 1201/MUM/2004 | Nov 2004 | IN | national |
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/IN05/00361 | 11/7/2005 | WO | 5/8/2007 |
